Orexo Interim Report Q2 2022
Good tailwind in the financial development Q2 2022 highlights · Total net revenues of SEK 147.8 m (142.8) · EBITDA of SEK -32.5 m (-41.1) · Net earnings of SEK -35.8 m (-73.7) · US Pharma segment (ZUBSOLV® US) net revenues of SEK 139.6 m (126.0), in local currency USD 14.2 m (15.0), US Pharma EBIT of SEK 77.2 m (61.6) · Cash flow from operating activities of SEK 14.5 m (-20.9), cash and invested funds of SEK 467.7 m (679.7) · Earnings per share before and after dilution amounted to -1.04 (-2.15) · Christine Rankin and Michael J Matly were elected as Board members